Phase III data for Jardiance shows improvement in HFpEF pati…
Results from the EMPEROR-Preserved Phase III trial have shown that Jardiance (empagliflozin) demonstrated a 21% relative risk reduction of cardiovascular death or hospitalisation for heart failure in adults with heart failure with preserved ejection fraction (HFpEF). The data, presented at the European Society of Cardiology (ESC) Congress on 27 August 2021, also […]
